Bill Castell becomes Chief Executive of Amersham International and sets a new course for the company, reducing its reliance on radioactive products and expanding into international export markets. The Healthcare (nuclear medicine) business, under John Maynard, will gradually move towards branded, innovative diagnostic and therapy products. The Life Sciences business, led by Ron Long, will add a new technology base in genomics and extend its market to include the pharmaceutical industry as well as academia.